Nanovibronix, Inc. (NASDAQ:FEED – Free Report) shares are set to reverse split before the market opens on Tuesday, September 1st. The 1-12 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, August 31st.
Nanovibronix Price Performance
FEED traded down $0.02 during trading on Friday, reaching $0.34. 465,195 shares of the company’s stock were exchanged, compared to its average volume of 5,272,438. Nanovibronix has a 1 year low of $0.29 and a 1 year high of $17.40. The company’s fifty day simple moving average is $0.44 and its 200-day simple moving average is $1.20. The stock has a market capitalization of $3.82 million, a P/E ratio of -0.04 and a beta of 1.38.
Nanovibronix (NASDAQ:FEED – Get Free Report) last announced its quarterly earnings data on Monday, August 17th. The company reported ($1.98) EPS for the quarter. The business had revenue of $0.24 million for the quarter. Nanovibronix had a negative net margin of 1,093.61% and a negative return on equity of 60.73%.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on FEED
Insider Activity
In other news, insider Christian Michael Glibert sold 210,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $0.69, for a total transaction of $144,900.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 12.20% of the stock is currently owned by insiders.
Nanovibronix Company Profile
Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.
The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.
Further Reading
- Five stocks we like better than Nanovibronix
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
